BCN Health Booster is a three-year programme for companies in the health sector to be accelerated through access to a laboratory at the Barcelona Science Park and a specialised acceleration programme by Biocat.
BCN Health Booster is an initiative of the Barcelona City Council, Barcelona Science Park, Barcelona Activa and Biocat.
What does it offer?
Discount on rent and general services:
Free acceleration programme, based on your needs imparted by Biocat:
20 hours per year of mentoring or specialised consultancy services
9 hours a year of sessions on reimbursement, customer discovery, IP, market access or regulatory issues
Pitch training, H&BIO Team dating, One-pager and brochure, Introduction to investors (TIRS)
Who is it for and selection criteria
Companies in the health sector that carry out an activity in the subsector of biotechnology, pharmacy, medical device or service company in the health sector. The candidate companies must be less than 5 years old since their incorporation or registration of activity, must be domiciled in Catalonia and must require the use of a laboratory to carry out their activity. Special value is given to those projects that present good prospects for technical and economic viability, a good team of promoters and that have a social impact with priority given to spin-offs of research centers, hospitals and universities.
Bioliquid is a biomedical technology-based company that focuses on women’s health. Its objective is to develop new tools to isolate fetal and tumor cells from a liquid biopsy, with the vision to improve non-invasive prenatal tests and prognostic, treatment, and monitorization of gynecological cancers.
DeepUll Diagnostics is aiming to fight sepsis and antimicrobial resistance with a fast and automated diagnostics system, supported by artificial intelligence therapy.
GAT Biosciences is advancing microalgae synthetic biology towards disruptive solutions for the production and delivery of recombinant biological drugs. They are developing novel non-injected and much more affordable biopharmaceuticals for infectious and high-prevalence chronic diseases.
Mimark is a spin-off of Vall Hebron Institute of Research which aims to improve women’s health by developing innovative diagnostic assays that solve unmet clinical issues related to gynecological disorders. Their first product is WomEC an in vitro diagnostic test that will provide an accurate, minimally invasive, and lower cost diagnosis of endometrial cancer, while guiding an optimal surgical treatment.
OneChain Immunotherapeutics is a spin-off company of the Josep Carreras Leukaemia Research Institute and ICREA founded by Dr. Pablo Menéndez. Its main objective is to improve people’s health through the development of new immunooncological therapeutic tools for the treatment of
a large number of neoplasms, mainly rare childhood leukemias or others with few therapeutic alternatives, providing innovative and viable pharmacological solutions.
Last day for applications
Resolution of award or refusal
Accelerator presentation event
Signing rental contracts
Start working in laboratories